- Home
- SEZL vs AKRO Comparison
SEZL vs AKRO Comparison
Compare SEZL & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEZL
- AKRO
- Stock Information
- Founded
- SEZL 2016
- AKRO 2017
- Country
- SEZL United States
- AKRO United States
- Employees
- SEZL N/A
- AKRO N/A
- Industry
- SEZL Diversified Financial Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- SEZL Finance
- AKRO Health Care
- Exchange
- SEZL Nasdaq
- AKRO Nasdaq
- Market Cap
- SEZL 3.3B
- AKRO 3.9B
- IPO Year
- SEZL N/A
- AKRO 2019
- Fundamental
- Price
- SEZL $106.71
- AKRO $49.65
- Analyst Decision
- SEZL Strong Buy
- AKRO Strong Buy
- Analyst Count
- SEZL 2
- AKRO 8
- Target Price
- SEZL $61.42
- AKRO $82.50
- AVG Volume (30 Days)
- SEZL 1.4M
- AKRO 1.9M
- Earning Date
- SEZL 05-07-2025
- AKRO 05-12-2025
- Dividend Yield
- SEZL N/A
- AKRO N/A
- EPS Growth
- SEZL 677.39
- AKRO N/A
- EPS
- SEZL 2.97
- AKRO N/A
- Revenue
- SEZL $329,060,890.00
- AKRO N/A
- Revenue This Year
- SEZL $33.01
- AKRO N/A
- Revenue Next Year
- SEZL $49.84
- AKRO N/A
- P/E Ratio
- SEZL $35.95
- AKRO N/A
- Revenue Growth
- SEZL 91.69
- AKRO N/A
- 52 Week Low
- SEZL $11.50
- AKRO $17.86
- 52 Week High
- SEZL $115.84
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- SEZL 79.89
- AKRO 63.34
- Support Level
- SEZL $96.69
- AKRO $44.94
- Resistance Level
- SEZL $115.84
- AKRO $49.29
- Average True Range (ATR)
- SEZL 6.44
- AKRO 3.33
- MACD
- SEZL 0.63
- AKRO 0.67
- Stochastic Oscillator
- SEZL 72.07
- AKRO 86.02
About SEZL Sezzle Inc.
Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase. Companies operations comprise one reportable segment, primarily deriving revenue from payment processing platform in North America.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.